Alpine Immune Sciences

Hope springs for April inhibition
Hope springs for April inhibition
EP Vantage
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Flag link:
Second Patient Death Shutters Alpine's Immuno-Oncology Program
Second Patient Death Shutters Alpine's Immuno-Oncology Program
BioSpace
Alpine Immune Sciences
davoceticept
patient death
clinical trials
ALPN-303
Flag link:
Death in Alpine's Keytruda combo trial triggers clinical hold, raises specter of earlier tragedy
Death in Alpine's Keytruda combo trial triggers clinical hold, raises specter of earlier tragedy
Fierce Biotech
Alpine Immune Sciences
davoceticept
Merck
Keytruda
clinical trials
patient deaths
Flag link:
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
BioSpace
Merck
Alpine Immune Sciences
cancer
ALPN-202
Keytruda
Flag link:
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Motley Fool
Biogen
Alkermes
Alpine Immune Sciences
Flag link:
ASCO 2021 movers – PDS wins, but big pharma reigns
ASCO 2021 movers – PDS wins, but big pharma reigns
EP Vantage
ASCO 2021
PDS Biotechnology
Spectrum Pharma
Black Diamond Therapeutics
Alpine Immune Sciences
Harpoon Therapeutics
Macrogenics
Flag link:
AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy
AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy
Endpoints
AbbVie
Mitchell Gold
Dendreon
ALPN-101
immunology
Alpine Immune Sciences
lupus
Flag link:
Former Dendreon CEO debuts new public company in reverse merger
Former Dendreon CEO debuts new public company in reverse merger
BioPharma Dive
Dendreon
reverse merger
Mitchell Gold
Alpine Immune Sciences
Nivalis
Flag link:
Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup
Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup
Forbes
Mitchell Gold
Dendreon
cancer immunotherapy
Alpine Immune Sciences
Flag link: